Monthly Obesity Drug Candidate Gets $1.5B Boost
Adults with obesity and related conditions may see more monthly treatment options as late-stage trials advance.
Updated on Nov. 21, 2026 in Diabetes

Live Poll
Do you think new weight-loss drugs will ever be affordable for you?
Blackstone Life Sciences has agreed to fund up to $1.5 billion of Pfizer's development costs for berobenatide, an investigational monthly GLP-1 receptor agonist peptide being studied for chronic weight management and obesity-related conditions. The funding runs through 2028, and Blackstone's payments are tied to certain regulatory and commercial milestones, so the arrangement is most relevant to people with obesity and related conditions in the United States.
Why it matters
The deal shows how large drug developers are sharing the cost of obesity research as Pfizer expands its pipeline of obesity and comorbidity trials. For people living with obesity, more trials in this area can mean more treatment options moving through development, though none of these candidates is approved yet.
This is a corporate co-funding arrangement rather than a study, so no trial results are available yet. The development program includes 10 ongoing and planned phase 3 trials, including evaluations for obstructive sleep apnea and knee osteoarthritis.
The players
Pfizer Inc
A global pharmaceutical company with a major obesity and metabolic disease pipeline, now advancing berobenatide through phase 3 trials.
Blackstone Life Sciences
The life sciences investment arm of Blackstone that co-funds late-stage drug development in exchange for milestone-based payments.
The details
Under a strategic co-funding agreement, funds managed by Blackstone will pay Pfizer's development costs for berobenatide through 2028, up to $1.5 billion. Berobenatide is evaluated both as a monotherapy and in combination with other nutrient-stimulated hormone peptides, including amylin analogs. Blackstone does not acquire any ownership in the drug, and Pfizer retains full operational control and decision-making over the program.
Timeline
2026: Pfizer plans to advance more than 20 obesity and comorbidity trials this year.
Through 2028: Blackstone funds up to $1.5 billion in berobenatide development costs.
Health Landscape
Monthly GLP-1 receptor agonist candidates like berobenatide extend a wave of obesity drug development that followed the approval of semaglutide for weight management. The arrangement also reflects a growing trend of investment firms co-funding late-stage pharmaceutical trials in exchange for milestone-based returns.
If you are living with obesity or a weight-related condition such as sleep apnea, this pipeline shows more options are being tested, though none of these candidates is approved yet. Any decision about future treatment is worth discussing with your doctor.
The takeaway
More obesity treatments are moving through late-stage development, which may expand options over time. If weight management is a concern for you, bring up current treatment choices and clinical trial options with your physician.
Further reading
For more on the medications shaping treatment of metabolic disease, explore our Diabetes coverage.
Source note: This article includes information reported by Sleep Review.
Live Poll
Do you think new weight-loss drugs will ever be affordable for you?





